ReviewTherapeutics and clinical risk management2022

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives.

Romain Iaxx et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.